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DETECTION OF ALZHEIMER’S DISEASE AND 
OTHER DISEASES USING AN IMPROVED 
PHOTOAFFINITY LABELING METHOD 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of U.S. Ser. 
No. 07/812,826, ?led Dec. 24, 1991 U.S. Pat. No. 
5,272,055. 
FIELD OF THE INVENTION 
The present invention relates to novel compositions, 
methods and test kits which use the procedure of pho 
toaf?nity labeling with nucleotide affinity probes, to 
detect disease using cerebral spinal ?uid, blood, tissue, 
or other specimens in a mammal. The present invention 
provides a method of diagnosis based on a disease 
speci?c biochemical marker macromolecule which, if 
present, can be identi?ed in a small biological sample 
from a patient. In particular, the present invention con 
cerns a method for diagnosing particular disease states 
using a disease-speci?c nucleotide binding protein and 
detecting the binding of that protein in the serum or 
cerebral spinal ?uid of a patient afflicted with that dis 
ease. 
BACKGROUND OF THE INVENTION 
Alzheimer’s disease (AD) is an idiopathic progressive 
dementia that will affect a large percentage of our aging 
population. To date its etiology is still unknown. The 
neurodegenerative disease is characterized by a chroni 
cally deteriorating course of impaired intellectual func 
tion and memory loss. 
Relatively little is known of the pathophysiological 
chain of events that leads to the premature dysfunction 
and death of affected neurons in Alzheimer’s disease 
patients. Multiple abnormalities have been reported in 
the brains of patients who have been diagnosed as hav 
ing Alzheimer’s disease, but it is dif?cult to determine 
which of these are the result of brain damage and which 
contribute to premature neuronal dysfunction and 
death. 
At the present time, the clinical diagnosis of Alzhei 
mer’s disease is one of exclusion. Secondary causes of 
loss of memory and impaired cognitive function may 
result from multiple infarcts, leading to so-called multi 
infarct dementia, or from intracranial mass lesions, such 
as subdural hematomas, brain tumors, or granulomas. 
Central nervous system infections of viral and bacterial 
origin, or even slow viral disorders such as Creutzfeldt~ 
Jakob disease, are part of the differential diagnosis. 
Furthermore, metabolic disorders involving vitamin 
B12 metabolism, thiamine or folate de?ciency, thyroid 
dysfunction, hepatic and renal failure, as well as drug 
toxicity may appear as dementia. Nevertheless, when all 
these secondary causes, many of which are reversible, 
are eliminated, cerebral atrophy of unknown cause or 
Alzheimer’s disease still covers the largest number of 
patients. 
The de?nitive diagnosis of Alzheimer’s disease is 
made by pathologic examination of postmortem brain 
tissue in conjunction with a clinical history of dementia. 
This diagnosis is based on the presence in brain tissue of 
intraneuronal neuro?brillary tangles and of neuritic 
(senile) plaques, which have been correlated with clini 
cal dementia. Although the cause of the abnormal cy 
toskeletal ?brils remains unknown, neuritic plaques are 
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thought to be composed of degenerating axons and 
nerve terminals as well as possible astrocytic elements, 
and they often exhibit a central amyloid protein core. 
The neuro?brillary tangles are interneuronal aggregates 
composed of normal and paired helical ?laments and 
presumably consist of several different proteins. The 
neurohistopathologic identi?cation and counting of 
neuritic plaques and neuro?brillary tangles requires 
staining and microscopic examination of several brain 
sections. 
It is problematic, however, that histochemical stain 
ing is not always reproducible, neuritic plaques and 
neuro?brillary tangles are not uniformly distributed, 
and histopathologic studies are time-consuming and 
labor-intensive. Moreover, there is no direct evidence 
that an accumulation of abnormal cytoskeletal ?brils 
contributes directly to premature dysfunction and death 
of the neurons; rather, the ?brils may simply be a mani 
festation of more fundamental cellular changes. The 
clinical and pathologic progression of Alzheimer’s dis 
ease is marked by a continuing loss of neurons from the 
cerebral cortex. However, neuritic plaques and neuro? 
brillary tangles may occur in nondemented elderly pa 
tients, as well as those af?icted with Alzheimer’s dis 
ease. 
Current research to develop both an understanding of 
the disease and a possible diagnostic test has centered on 
the amyloid protein and its precursor protein. Theoreti 
cally, diagnosis has been based on the deposition of 
amyloid containing plaques in the cortical region in the 
brain of individuals affected with Alzheimer’s disease. 
Such diagnostic methods have been disclosed in, for 
example, U.S. Pat. Nos. 4,666,829, 4,701,407, 4,816,416 
and 4,933,156. 
However, amyloid deposits are also found in the 
brains of aged individuals who have never displayed 
signs of dementia. For example, a recent article (J. Biol. 
Chem, 265:15977 (1990)) has shown that there were no 
differences in the primary structure of precursor amy 
loid protein from platelets of normal individuals and 
that of Alzheimer’s disease patients. Therefore, while 
amyloid protein may be involved in Alzheimer’s dis 
ease, other methods have been pursued to identify char 
acteristics more uniquely related to a patient with Alz 
heimer’s disease. For instance, U.S. Pat. No. 4,727,041, 
issued to Aroonsakul, discloses a comparative test for 
the diagnosis of Alzheimer’s disease in humans by deter 
mining levels of somatotropin and somatomedin-C in 
the patient’s blood sera drawn at intervals following 
administration of an L-dopa provocative test. 
Immunoassay methods have also been developed for 
detecting the presence of neurochemical markers in 
Alzheimer’s disease patients. U.S. Pat. Nos. 4,728,605 
and 4,801,533, issued to Fudenberg et al., disclose com 
parative methods for diagnosing degenerative disease of 
the central nervous- system, particularly Alzheimer’s 
disease, by measuring immunological parameters and 
interactive T cells from a patient’s peripheral blood. 
U.S. Pat. No. 4,806,627, issued to Wisniewski et at., 
discloses protease resistant proteins which comprise 
scrapie-associated ?brils and a scrapie-speci?c mono 
clonal antibody to distinguish certain neurological dis 
ease-caused human dementias from Alzheimer’s disease. 
However, none of the known methods of diagnosis 
have proven to be a reliable means of detection of A12 
heimer’s disease in all patients, particularly at early 
stages of the disease. As a result, alternative methods of 
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diagnosis have been proposed which rely on analyzing 
the cerebral spinal ?uid drawn from the affected pa 
tients. For example, Warner in Anal. Chem, 59:1203A 
1204A (1987), has proposed a method for detecting 
Alzheimer’s disease related amyloid protein in the cere 
bral spinal ?uid of affected patients. 
US Pat. No. 4,874,694, issued to Gandy et al., dis 
closes a diagnostic method for neurological and psychi 
atric disorders, such as Alzheimer’s disease. The 
method involves incubating cerebrospinal ?uid from a 
patient in the presence of 32P-labeled adenosine triphos 
phate (ATP) and a protein kinase which was capable of 
transferring phosphate from the ATP, followed by elec 
trophoresis. The resulting autoradiographic pattern of 
the fractionated, labeled sample is then compared with 
predetermined autoradiographic patterns from known 
neurological and psychiatric pathologies to ascertain 
the particular pathology of the patient’s cerebrospinal 
?uid being analyzed. However, the method disadvanta 
geously is based only on autoradiographic patterns. It 
fails to identify disease-speci?c marker proteins in the 
cerebral spinal ?uid. 
Studies by Khatoon et at. (Ann. of Neurology, 
26:210-215 (1989)) have shown that an interaction of an 
important cellular protein, tubulin, in the formation of 
microtubules was aberrant in preparations made from 
the brain tissues of patients with Alzheimer’s disease. 
The inhibition was monitored by measuring the interac 
tions of a radioactive photoaf?nity probe of the nucleo 
tide GTP (guanosine-S’-tri-phosphate) with the proteins 
that require GTP to effect microtubule formation. 
Molecules containing azido groups have been shown 
to form covalent bonds to proteins through reactive 
nitrene intermediates, generated by low intensity ultra 
violet light. Potter & Haley, Meth. in Enzymol, 
91:613-633 (1983). In particular, 2- and 8-azido ana 
logues of purine nucleotides have been used as site di 
rected photoprobes to identify nucleotide binding pro 
teins in crude cell extracts. Owens & Haley, J. Biol. 
Chem. 259:14843-14848 (1984); Atherton et al., Bio. of 
Reproduction, 32:155-171 (1985). The 2-and 8-azido 
nucleotides have also been used to map nucleotide bind 
ing domains of puri?ed proteins. Khatoon et al., Ann. of 
Neurologz, 26:210-215 (1989); King et al., J Biol. Chem, 
264:10210-10218 (1989); and Dholakia et al., J. Biol. 
Chem, 264:20638-20642 (1989). 
Photoaf?nity probes have been used to determine 
speci?c nucleotide binding sites on a biologically active 
recombinant peptide molecule. Campbell et al., PNAS, 
87:1243-1246 (1990). The probes have also been used to 
study enzyme kinetics of puri?ed proteins. Kim et al., J. 
Biol Chem, 265:3636-3641 (1990). 
Thus, considerable effort has been devoted to devel 
oping systems for the de?nitive diagnosis of Alzhei 
mer’s disease in patients. However, until the method of 
the present invention, no reliable non-invasive test for 
Alzheimer’s disease has been developed. The major 
drawback of the most de?nitive determination of Alz 
heimer’s disease known in the art has been that direct 
analysis of pathological tissue could only be performed 
postmortem on affected individuals. 
Because Alzheimer’s disease is progressive in nature, 
the ef?ciency of a cure could critically depend upon 
early detection. Additionally, the value of any new 
therapy in alleviating or curing the disease could be 
better ascertained if a rapid, safe and effective diagnos 
tic procedure were available to monitor the progress of 
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Alzheimer’s disease patients following treatment. The 
same can be said for other disease states, such as cancer. 
Therefore, there remains a long-felt need in the art 
for a reliable, accurate, safe and effective method for 
the diagnosis of Alzheimer’s disease, as well as a means 
for the diagnosis and differentiation of other diseases, 
syndromes or pathologies. A method for the identi?ca 
tion and characterization of a disease-speci?c biochemi 
cal marker and the identi?cation of such a marker is 
needed. 
OBJECTS AND SUMMARY OF THE 
INVENTION 
It is, therefore, an object of this invention to provide 
a method for diagnosing Alzheimer’s disease compris 
ing detecting a speci?c nucleotide binding protein 
within the extracted cerebral spinal fluid of patients 
af?icted with Alzheimer’s disease. 
It is another object of the present invention to pro 
vide a method for diagnosing Alzheimer’s disease com 
prising detecting a speci?c nucleotide binding protein 
within the extracted cerebral spinal ?uid of normal 
patients, but which is not photolabeled in the cerebral 
spinal ?uid of patients af?icted with Alzheimer’s dis 
ease. 
It is a further object of the present invention to pro 
vide a composition for use in a test kit for the diagnosis 
of Alzheimer’s disease comprising a radioactive pho 
toaf?nity probe which will selectively bind to a speci?c 
nucleotide binding protein within the extracted cerebral 
spinal ?uid of a patient af?icted with Alzheimer’s dis 
ease, but which is not found in the cerebral spinal ?uid 
of a normal subject. 
A still further object of the present invention is to 
provide a composition for use in a test kit for the diag 
nosis of Alzheimer’s disease comprising a radioactive 
photoaffmity probe which will selectively bind to a 
speci?c nucleotide binding protein within in the cere 
bral spinal ?uid of a normal patient, but which is not 
found in the cerebral spinal fluid of a patient af?icted 
with Alzheimer’s disease. 
It is an additional object of the present invention to 
provide antibodies to the respective Alzheimer’s disease 
related proteins, as identi?ed by the method of the cur 
rent invention, for the purpose of providing an immuno 
assay to recognize the Alzheimer’s disease speci?c pro 
teins in the cerebral spinal ?uid, blood plasma, or tissues 
of the human body. 
It is another object of the present invention to pro 
vide a method, using the procedure of photoaf?nity 
labeling with nucleotide affinity probes, to diagnose 
neurological disorders using cerebral spinal ?uid, 
blood, tissue, or other biological samples from a mam 
mal. The presence or development of a neurological or 
psychiatric pathology including, but not limited to, 
Alzheimer’s disease, epilepsy, scrapies-type disorders, 
amyotrophic lateral-sclerosis (ALS or Lou Gehrig’s 
disease), Down’s syndrome, Behcet disease, encephali 
tis, Huntington disease, Creutzfeldt-Jakob disease, Par 
kinson disease, AIDS dementia, multiinfarct dementia, 
dystonia, ataxia, schizophrenia, neurosyphilis, cerebral 
toxoplasmosis, brain irradiation, brain tumor, Guillain 
Barre syndrome, tremor, multiple sclerosis, head 
trauma, acute and chronic encephalitic and vascular 
disease, or other disease states such as cancer or eating 
disorders such as anorexia can be detected. 
A still further object of the present invention is to 
provide a method for aiding in the diagnosis of a spe 
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ci?c neurological disease wherein the neurological dis 
ease demonstrates elevated glutamine synthetase in the 
cerebral spinal ?uid as detected by photoaf?nity label 
ing with a radioactive nucleotide photoaf?nity probe, 
and wherein the photoincorporation of that probe is 
considerably elevated by the addition of micromolar 
levels of Mn“ metal ion. 
Yet a further object of the present invention is to 
provide a method for aiding in the diagnosis of a spe 
ci?c neurological disease wherein the neurological dis 
ease shows an elevation of one or more proteins readily 
observable after dialysis or ?ltration of the small mole 
cules away from the proteins of CSF. 
A still further object of the present invention is to 
provide a method for aiding in the diagnosis of other 
disease states, including non-neural disease states, such 
as cancer, wherein a sample obtained from a patient 
suffering from that disease shows an elevation or a de 
crease in one or more proteins that are detectable by 
photoaffinity labelling. 
Additional objects, advantages and novel features of 
the invention will be set forth in part in the description 
which follows, and in part will become apparent to 
those skilled in the art on examination of the following 
description, or may be learned by practice of the inven 
tion. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a photograph of an autoradiogram made 
from a sodium dodecyl sulfate-polyacrylamide gel 
(SDS-PAGE) on which human cerebral spinal ?uid 
proteins were separated after being photolabeled with 
[32P]8N3ATP. The cerebral spinal ?uid samples were 
obtained from patients known to have epilepsy (lanes 
E), Parkinson’s disease (lanes P), Alzheimer’s disease 
(lanes AD) or from normal, age-matched control sub 
jects (lanes N). The autoradiograph shows that a pro 
tein of about 42,000 M,is photolabeled only in the cere 
bral spinal ?uid of a patient with Alzheimer’s disease. 
Also, the selectivity of this interaction with naturally 
occurring ATP is demonstrated by the prevention of 
photolabeling by [32P]8N3ATP when ATP is present as 
shown in the last four lanes. 
FIGS. 2A and 2B is a photograph of two combined 
autoradiographs of the two 10% SDS-PAGE shown in 
FIGS. 2 C and D on which human cerebral spinal ?uid 
proteins were separated after photolabeling with 
[32P]8N3cAMP. These are the same patient samples 
used in FIG. 1. Samples were from patients with epi 
lepsy (lanes E), Parkinson’s disease (lanes P), Alzhei 
mer’s disease (lanes AD), or from normal control sub 
jects (lanes N). The lane labeled “markers” contained 
proteins of known molecular weight which were used 
to determine the approximate molecular weight (M, 
value) of the cerebral spinal fluid proteins. The SDS 
PAGEs were stained with Coomassie Brilliant Blue R 
(CBB) to detect cerebral spinal ?uid proteins of differ 
ent M,values and are shown in FIGS. 2 C and D. Prote 
ins photolabeled with [32P]8N3cAMP, since they are 
now radioactively tagged, were located by autoradiog 
raphy as shown in FIGS. 2A and 2B. The data in the 
autoradiographs of FIGS. 2A and 2B show that a pro 
tein of about 68,000 M, is photolabeled only in the cere 
bral spinal ?uid of normals, epileptics and Parkinson’s 
diseased individuals. This 68,000 M, protein is not 
photolabeled in the cerebral spinal ?uid of Alzheimer’s 
diseased patients. 
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FIG. 3 shows two bar graphs which compares the 
photolabeling with [32P]2N3ATP of the 42,000 M, pro 
tein of cerebral spinal ?uid (3A) from Alzheimer’s dis 
eased patients with that of puri?ed glutamine synthetase 
(GS) (FIG. 3B). Photolabeling was done under differ 
ent conditions (e. g., with or without added NH4+) and 
the proteins were separated by SDS-PAGE. The 42,000 
M, band was excised and the level of 321) incorporated 
was determined. Such experiments were used to show 
that the 42,000 M, protein and GS behaved identically 
under several different biochemical conditions and, 
Western blotting with the GS speci?c antibody data, 
con?rmed that the 42,000 M, protein was indeed GS. 
FIG. 4 is a photograph of an autoradiograph made 
from an SDS-PAGE on which human cerebral spinal 
?uid proteins from Amyotrophic Lateral Sclerosis 
(ALS or Lou Gehrig’s disease) or Alzheimer’s Diseased 
(AD) patients were separated after photolabeling with 
[32P]8N3ATP or [32P]8N3GTP. This autoradiograph 
shows that neither [32P]8N3ATP or [32P]8N3GTP de 
tects the AD speci?c 42,000 M, protein in the cerebral 
spinal ?uid of patients with ALS. This further con?rms 
the selectivity of this approach as a diagnostic test for 
AD. However, using [32P]8N3GTP a protein of about 
55,000 M, is photolabeled in only the ALS cerebral 
spinal ?uid. Further tests indicate that this protein is 
only found in the cerebral spinal ?uid of ALS patients 
and is probably diagnostic of this disease. 
FIG. 5A is an SDS-PAGE gel showing pure GS. 
FIG. 5B is an autoradiograph of the SDS-PAGE gel of 
FIG. 5A which shows that the presence of Mn2+ 
greatly enhances the photolabelling of GS by 
[32P]8N3ATP. 
FIG. 6A is an SDS-PAGE gel demonstrating 
photolabeling of two samples from patients in an early 
stage of AD. FIG. 6B is an autoradiogram of the gel 
from FIG. 6A showing the enhancement of photolabel 
ing of GS and four other proteins in these samples by 
Centricon ?ltration. 
FIG. 7 is an autoradiograph made from an SDS-PAG 
on which photolabeled proteins from blood serum of 
normal, sickle cell anemia and cancer patients were 
separated. 
FIG. 8 is an autoradiograph made from an SDS-PAG 
on which photolabeled proteins from blood serum of 
normal and cancer patients were separated subsequent 
to spin ?ltration. Signi?cant changes were observed in 
the level of photolabelling of several proteins especially 
those below 40,000 M, values. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS OF THE 
INVENTION 
In accordance with the present invention, novel com 
positions, methods and test kits are provided, using the 
procedure of photoaf?nity labeling with nucleotide 
affinity probes, to detect a neurological disorder using 
cerebral spinal ?uid, blood, tissue, or other biological 
samples from a mammal. The presence or development 
of a neurological or psychiatric disorder can be de 
tected. The invention concerns a composition, the prep 
aration of the composition and a method for diagnosing 
or detecting Alzheimer’s disease. The method involves 
the use of a disease-speci?c nucleotide binding protein 
within the extracted cerebral spinal ?uid of a patient 
af?icted with a neurological disorder such as Alzhei 
mer’s disease. 
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The present invention provides a method for detec 
tion using a disease-speci?c biochemical marker macro 
molecule which, if present, can be identi?ed in a small 
biological sample obtained from a patient. The speci?c 
biochemical marker macromolecule is dependent on the 
disease state which is being detected. 
The standards for testing for neurological disease 
states are established by obtaining cerebral spinal ?uid 
samples from a number of patients, each of whom suf 
fers from a particular disorder which is clinically mani 
fested by marked dementia or de?ciency in cognitive 
function, including memory or attention. 
Speci?cally the neurological diseases of the nervous 
system, referred to in the method of the present inven 
tion are those diseases, disorders, or syndromes which 
are either the cause of or the result of a biochemical 
alteration in the brain, brain stem, spinal cord or gan 
glia. The diseases can include, but are not limited to, 
Alzheimer’s disease, epilepsy, scrapies-type disorders, 
amyotrophic lateral sclerosis (ALS or Lou Gehrig’s 
disease), Down’s syndrome, Behcet disease, encephali 
tis, Huntington disease, Creutzfeldt-Jakob disease, Par 
kinson disease, AIDS dementia, multiinfarct dementia, 
dystonia, ataxia, schizophrenia, neurosyphilis, cerebral 
toxoplasmosis, brain irradiation, brain tumor, Guillain 
Barre syndrome, tremor, multiple sclerosis, head 
trauma, acute and chronic encephalitic and vascular 
disease. Moreover, the present method of detection 
could also be used to monitor any event which causes 
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brain cell death which results in the accumulation of 30 
nucleotide binding proteins in the cerebral spinal ?uids, 
such as, minor to severe brain damage caused by high 
fever or head injury. The present invention can also be 
utilized to detect other disease states such as cancer, 
which also lead to alterations in the level of biochemical 
marker macromolecules. 
By the present invention it has been shown that a 
disease-speci?c unique biochemical marker macromole 
cule, in particular a speci?c nucleotide binding protein, 
can be identi?ed in the spinal ?uid of patients suffering 
from certain neurological disorders, particularly pa 
tients suffering from Alzheimer’s disease. Additionally, 
it has also been shown that proteins obtained from ?uid 
samples from cancer patients show altered photolabel 
ing compared to normal patients. 
Brie?y, a typical analysis of a cerebral spinal ?uid 
sample or serum by the method of the present invention 
would proceed as follows. These steps and quantities 
are only offered as guidelines for the practice of the 
present invention. 
A small portion, usually between 10 to 30 microliters 
of cerebral spinal ?uid or serum is mixed with concen 
trations of about 10 to 30 uM of a radioactive radioaf 
finity probe for 0.5 to 1.0 minutes, followed by 30 to 120 
seconds of exposure to ultraviolet light. Photoincorpo 
ration of [32P]8N3ATP into GS is preferably elevated 
by the addition of micromolar levels of Mn2+ metal ion. 
Suitable levels of Mn2+ metal ion range from 1.0 uM to 
1000 uM, more preferably 5 nM to 50 p.M, and most 
preferably 10 pM. The sample is precipitated, then 
immediately solubilized with a solution containing de 
tergent and subjected to protein fractionation, such as 
by gel electrophoresis. In a preferred embodiment, 
prior to photolabeling, CSF or serum samples are ?l 
tered by dialysis or ?ltration using a ?ltration device 
such as a Centricon ?lter. Such ?ltration or dialysis 
removes small molecules from the CSF or serum which 
interfere with photolabeling. 
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The ?nished gel is placed in a holder containing 
X-ray ?lm for autoradiography. The radioactive pro 
tein (the result of chemical crosslinking between the 
radioactive photoprobe and the binding protein) in the 
gel can be located since the radioactivity will expose the 
adjacent section of the ?lm resulting in a darkened 
(black) appearance. 
The sample subjected to analysis can be selected from 
any biological sample capable of carrying the unique 
nucleotide binding protein. Examples of such biological 
samples include body ?uids such as spinal ?uid, blood 
or serum. However, samples tested for the unique nu 
cleotide binding protein by the present method are most 
preferably cerebral spinal ?uid, also referred to as cere 
brospinal ?uid or serum. 
The protein composition of cerebral spinal ?uid is 
largely derived from serum proteins which leak into the 
subarachnoid space through imperfections in the blood 
brain barrier, such as the area postrema, and perhaps 
across the richly vascular choroid plexus, through 
which cerebral spinal ?uid is generated as an ultra?l 
trate. The cerebral spinal ?uid has signi?cantly fewer 
proteins than cytosolic fractions. Some proteins, such as 
immunoglobulins, may be generated in the subarach 
noid space during in?ammation. Since the cerebral 
spinal ?uid bathes the surfaces of cerebral and cerebel 
lar cortices, the caudate, brain stem and spinal cord, 
each of the structures contributes to the total cerebral 
spinal ?uid protein. 
The inventive method need not be limited to human 
patients, but may be extended to any mammal af?icted 
with certain diseases or syndromes, including scrapies 
or “Mad Cow” disease.‘ 
The sample may be drawn as either ventricular cere 
bral spinal ?uid or as lumbar cerebral spinal ?uid, or as 
a blood sample. Occasionally, however, sample proteins 
are concentrated by various procedures to better visual 
ize the speci?c nucleotide binding protein. Vacuum 
procedures include, for example, lyophilization or 
Speed-vac concentration. Also, precipitation of cere 
bral spinal ?uid by ammonium sulfate or polyethylene 
glycol could be used to concentrate the nucleotide bind 
ing proteins. Thus, there are a variety of techniques 
well known in the art that would be suitable in the 
practice of the present invention. 
Detection of a speci?c nucleotide binding protein can 
be accomplished by measuring a label crosslinked to the 
selected biochemical marker macromolecule after reac 
tion, photochemical or chemical crosslinking, and re 
moval of free probe. The particular label bound to the 
macromolecule will include, for example, a radioactive 
nucleotide introduced by replacing an equivalent non 
radioactive atom with 32P, tritium, carbon-l4 or other 
radioactive atom or ligand analog modi?ed with a 
linker group to provide a linking site to the crosslinking 
molecule. A particularly preferred radioactive label in 
the present invention is a- or 'y-32P. 
The ligand or linker group, if present on the speci?c 
biochemical marker macromolecule, will have chemical 
characteristics or functionalities such that a small radio 
active nuclide labeled molecule, or a chromogenic, 
?uorogenic, or luminescent molecule, or a magnetic 
particle can be attached to the ligand or linker group. 
The ligand will have the chemical characteristics such 
that a receptor molecule is available or capable of being 
elicited, such as an antibody molecule to the ligand. The 
receptor molecule can be conjugated to a radioactive 
nuclide labeled molecule, or to a chromogenic, ?uoro 
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genic, or luminescent dye molecule, or to a magnetic 
particle or to an enzyme system capable of generating a 
chromogenic, ?uorogenic, and/or luminescent product 
via appropriate substrates. 
Most preferably the unique biochemical marker mac 
romolecule, particularly the speci?c nucleotide binding 
protein, is detected in the sample by a radioactively 
labeled photoaf?nity probe. A nucleotide photoaf?nity 
probe is a nucleotide derivative which has affinities for 
binding sites and biological activity comparable to the 
unaltered nucleotide. Exposure to certain wavelengths 
of light converts the analog to a very reactive interme 
diate, typically a nitrene or a carbene, which may result 
in covalent incorporation into the binding site if it is 
bound to a protein. 
There are certain advantages to using photoprobes 
over conventional chemical probes. One advantage is 
that Km, Kd, and K,- values can be determined in the 
absence of activating light. Another advantage is that 
complex systems such as ribosomes, membranes, and 
whole cell sonicates can be studied. In this manner, an 
in vivo situation may be more closely approximated and 
information may be obtained that might otherwise be 
lost in a puri?ed system. 
Many nucleotide photoaf?nity probes may be synthe 
sized and used successfully. The photoaf?nity com 
pounds of the invention may include, for example, pu 
line triphosphate azido analogs, which may be exempli 
?ed by adenine analogs, although guanine analogs can 
be substituted therefor. For example, purine binding 
sites may be effectively labeled by the following, and 
their 5'-mono-, di- and triphosphates: oligomers of a 
single azidoadenylyl species, such as, for example: 2 
azido or 2-azidoadenylyl(2’-5’)2-azidoadenylyl(2'-5')2 
azidoadenosine; 2-azido or 8-azidoadadenosine; 8 
azidoadenylyl(2’-5')-8-azidoadenylyl(2’-5’)8 
azidoadenosine; 8-azidoadenylyl(2’-5’)-8 
azidoadenylyl(2’-5’)8-azidoadenylyl-(2'-5’)8 
azidoadenosine; 2,8-diazidoadenylyl(2’-5’)2,8 
diazidoadenylyl(2’-5')2,S-diazido-adenosine; 2,8 
diazidoadenylyl(2'-5’)2,8-diazidoadenylyl(2'-5')2,8 
diazidoadenylyl(2'-5')2,8-diazidoadenosine; also oligo 
mers of AMP and a single azidoadenylyl species, such 
as, for example: 2-azidoadenylyl(2’-5’)2-(2’-5’)adeno 
sine; adenylyl(2’-5’)8-azidoadenylyl(2’-5’)8-azidoadeno 
sine; also oligomers containing more than one azidoade 
nylyl species, such as, for example: 2-azidoadenylyl(2' 
5’)8-azidoadenylyl(2’-5')2-azidoadenosine; also oligo 
mers resulting from any combination of the monomers 
AMP, 2-azido-AMP, 8-azido-AMP and/or 2,8-diazido 
AMP, provided that at least one such monomer incor 
porated into the oligomer is an azido-AMP species. 
In addition photoaf?nity compounds of the invention 
may also include photoactive coenzyme analogs of 
NAD+, exempli?ed by nicotinamide 2-azidoadenosine 
dinucleotide (2-azido-NAD+), or analogs of NADH, 
exempli?ed by nicotinamide Z-hydrazidoadenosine di 
nucleotide (2-azido-NADH). 
Alternatively, guanine moieties can be de?ned in 
each of the exemplary compounds in place of the re 
spective adenine moieties. Therefore, certain most pre 
ferred compounds of the present invention are synthe 
sized from azidoguanosine 5'-triphosphates or combina 
tions thereof, or from azidoguanosine 5'-triphosphates 
and ATP. The latter provides a (2'-5’)oligomer contain 
ing both guanylyl and azidoguanylyl moieties. 
Furthermore, photoaf?nity compounds of the present 
invention may also include, for example, pyrimidine 
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derivatives. For instance, photoactive analogs of dUTP, 
such as 5-azido-2'-deoxyuridine 5’-triphosphate (5 
N3dUTP), may be synthesized from dUMP and provide 
a pathway for the synthesis of other useful 5-substituted 
uridine nucleotides. The S-diazouridine nucleotides 
may, for example, serve as active-site-directed photoaf 
?nity probes or as substrates for polymerizing enzymes 
to generate additional photoactive nucleic acids which 
remain stable to extremes of pH and which remain ef 
fective photolabeling reagents in the presence of reduc 
ing agents. Moreover, since the synthesis of S-NgdUTP 
employs mild conditions, it is also possible to synthesize 
homopolymers of 5-N3dUTP to provide single-stranded 
photoactive DNA of de?ned length. Using 5N3UTP 
one can similarly produce photoactive RNA. 
Generalized methods for the synthesis of aryl azides 
include nucleophilic displacement of a bromine, chlo 
rine or nitro group by an azide ion or the addition of 
sodium azide to an acidic solution containing a diazo 
tized primary aromatic amine. 
To date the most widely used 8-azidopurine is proba 
bly 8N3cAMP. One of the advantages of 8N3cAMP is 
that in mammalian systems there are only two types of 
proteins that are known to bind cAMP with high affm 
ity, the cAMP phosphodiesterases and the regulatory 
subunits of the cAMP-dependent protein kinases. The 
photoprobes [32P]8N3cAMP and [32P]8N3ATP have 
been employed to study, for example, the mechanisms 
of action of cAMP-dependent protein kinase. Photoac 
tive analogs of GTP, e.g., [32P]8N3GTP, have been 
developed to study, for example, tubulin polymeriza 
tion, while photoactive analogs of UTP, e.g., 
[32P]5N3dUTP have been generated to study, for exam 
ple, the binding site of DNA binding proteins. 
Preferred compounds of the present invention are 
synthesized from azidoadenosine 5’-triphosphates or 
combinations thereof, which provide a (2'-5’)oligomer 
containing both adenylyl and azidoadenylyl moieties. A 
preferred photoaffmity compound for the identi?cation 
by the present invention of the Alzheimer’s disease 
speci?c protein is 8-azidoadenosine 5'-triphosphate 
(8N3ATP), while a particularly preferred photoaf?nity 
compound of the present invention is 2-azidoadenosine 
5'-triphosphate (2N3ATP). A particularly preferred 
photoaf?nity compound for the identi?cation by the 
present invention of the ALS-speci?c protein is 8 
azidoguanosine 5'-triphosphate (8N3GTP). Particularly 
preferred photoaf?nity compounds for the identi?ca 
tion by the present invention of the cancer-speci?c 
proteins are 8-azidoadenosine 5'-triphosphate 
(8N3ATP) and 2-azidoadenosine 5’-triphosphate 
(2N3ATP). 
Nonradioactive labels can be divided into two cate 
gories (i) chromogenic, ?uorogenic, or chemilumines 
cent dyes or (ii) ligands. Dyes are normally of from 8 to 
40 carbon atoms, preferably from 9 to 30 carbon atoms. 
The dyes further normally contain from 1 to 10 hetero~ 
atoms usually oxygen, nitrogen, or sulfur, and normally 
contain no halogen atoms or up to 10 halogen atoms 
usually iodine, bromine, chlorine, or ?uorine. 
Chromogenic dyes may include phenol sulfoneph 
thalein and analogs of tetrazolium. 
Fluorogenic dyes may include ?uorescein isothiocya 
nate, dichlorotriazinylamino ?uorescein, morpholinor 
hodamine isothiocyanate, tetramethylrhodamine isothi 
ocyanate, and 4-acetamido»4-isothiocyano-stilbene-2 
with 2’-disulfonic acid. Fluorescent purine derivatives 
may also include, for example, the ?uorescent GTP 
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analog 2'3’-O-(2,4,6-trinitrocyclohexadienyl-idine) 
guanosine 5'-triphosphate (TNP-GTP), or the equiva 
lent ?uorescent ATP derivative (TNP-ATP). 
Chemiluminescent dyes may include 5-amino-2,3 
dihydro-phthalazine-1,4-dione (luminol), derivatives of 
isoluminol and acridinium esters. 
Any ligand may be employed for which an appropri 
ate receptor may be found to have satisfactory specific 
ity for the ligand. 
Various methods or protocols may be employed in 
measuring the amount of the labels. These protocols can 
include for example, radioimmunoassay (RIA), im 
munoradiometric assay (IRMA), sandwich IRMA, 
?uoroimmunoassay (FIA), chemiluminescent assays, 
bioluminescent assays, and enzyme linked immunosorb 
ent assays (ELISA) among others. 
The labeled probe of the present invention can be 
used in any conventional hybridization technique. Hy 
bridization formats which may be useful in the practice 
of the present invention include those in which the 
sample is immobilized on a solid support (solid-phase 
hybridization) and those wherein the species are all in 
solution (solution hybridization). Solution hybridization 
is preferred in the present method. Another method of 
interest is the sandwich hybridization technique. 
Certain factors are considered when a unique bio 
chemical macromolecular marker is identified by means 
of a radioactive photoaf?nity label, as is the preferred 
method of the present invention. For example, consider 
ation should be given to: (a) temperature of incubation 
and photolysis, (b) length of incubation and photolysis, 
(0) concentration of photoaf?nity reagent, (d) binding 
affinity of protein for the reagent and natural ligands, 
(e) stability of the photoaf?nity reagent in each particu 
lar system, (f) ionic strength, pH, cofactors, (g) protein 
concentration, (11) intensity of photolyzing light, (i) 
quenching of reaction and separation of unused label, 
and (i) interpretation of results. Potter & Haley in Meth. 
in Enzymol, 91:613-633 (1983) provide a detailed ac 
count of preferred procedures for labeling a speci?c 
biochemical marker macromolecule in a sample with a 
photosensitive purine triphosphate azide analog. 
Temperature of the photolysis reaction between the 
sample and the selected photoaf?nity label can range 
from 0° C. to room temperature (25° C.) or above. How 
ever, the exchange rate between bound and unbound 
cAMP or 8-N3cAMP approaches negligible levels at 0° 
C., and is greatly increased at room temperature. Con 
versely, once 8-N3cAMP is bound to the speci?c mac 
romolecular marker, it may be cold trapped onto the 
protein by dropping the temperature to nearly 0° C. 
Therefore, the most preferred procedure includes prein 
cubation of the components at room temperature, and 
photolysis in plates set on ice to reduce the temperature 
to approximately 0° to 4° C. By the present invention, 
the sample is preferably incubated at room temperature 
with the radioactive photoaf?nity probe for approxi 
mately 0.5 to 1.0 minutes. Most preferably the mixture is 
vortexed for 6 seconds followed by an additional 24 
seconds of mixing, immediately followed by placing the 
sample on ice for photoactivation. 
The concentration of photoaf?nity reagent must be 
compatible with the binding affinity of the protein to be 
labeled. Excessively high concentrations, however, can 
lead to undesirable nonspeci?c labeling which increases 
linearly with concentration. Best results can be obtained 
by experimentally determining the optimum concentra 
tion for photoincorporation. Directly related to the 
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determination of concentration is the stability of the 
reagent. The stability of the reagent can be determined 
by thin-layer chromatography, e. g., by ?uorescent cel 
lulose thin-layer chromatography. 
Ionic strength, pH, cofactor, and metal ion concen 
trations can each affect protein structure, and are 
readily adjusted by those skilled in the art to achieve 
optimal labeling conditions. For example, photoincor 
poration of the photoaf?nity probe 8N3ATP into GS is 
preferably elevated by the addition of micromolar lev 
els of Mn2+ metal ion. In addition protein concentration 
can be determinative of the photoresponse. Also, both 
ammonia and glutamate (co-substrates) enhance 
photolabelling if Mg2+ or Mn2+ is present. The higher 
the protein content of the sample, the denser the solu 
tion becomes to light. Therefore, in a denser solution, 
less UV light reaches the photoreagent per unit of time, 
decreasing the rate of photoincorporation. Aggregation 
of the protein can also affect the binding time of the 
reagent to the protein, thereby increasing or decreasing 
photoincorporation. One must experimentally redeter 
mine optimal photolysis time when changing protein 
concentration if maximum incorporation of the photola 
bel is desired. 
By the present invention, it is preferable to photolabel 
' a small 10 to 30 microliter aliquot of cerebral spinal ?uid 
with radioactively-labeled photoaf?nity probe (i.e., 
[32P]2N3ATP or [32P]8N3ATP) resulting in an approxi 
mate ?nal concentration of 10 to 30 uM for detection of 
the Alzheimer’s disease-speci?c 42,000 M, protein. 
Most preferably, the aliquot of each cerebral spinal ?uid 
analyzed is 15 ul. However, limits of detection are im 
proved, at little expense, by using larger sample vol 
umes or by concentrating the spinal ?uid. ‘ 
In the alternative, the sample may be labeled with 
[32P]8N3cAMP, in which case the sample is placed on 
ice to reduce the temperature to about 0° C. and photo 
activated. In experiments conducted to evaluate the 
absence of [32P]8N3cAMP photoinsertion into the pro 
tein of interest in a cerebral spinal ?uid sample, the 
preferred concentration of [32P]8N3cAMP is main 
tained at not more than 5 uM. 
Detection of the labeled protein occurs following an 
appropriate, predetermined incubation time to effect a 
reaction, and is calculated on the basis of the sample and 
the selected photoaf?nity probe. 
The intensity of the photolyzing light is such that 
maximum photoincorporation can be obtained in a mini 
mum amount of time without appreciable change in 
temperature or damage to the biological sample. Prefer~ 
ably the photolysis is achieved at 254 nm with an ultra 
violet light source. 
Ultraviolet (UV) light is essential for the activation of 
the photoprobe treated samples, but only a low intensity 
UV light is necessary. The intensity of the UV light can 
range from 180 to 800 nW/cm2 by conventional sources 
to 4000 p.W/cm2 and above when a high intensity 
source is used to achieve rapid photolysis. 
Photolysis times range from 15 seconds to 5 minutes 
and must be experimentally determined for each reac 
tion system. For lamps having intensities of 180-800 
uW/cmZ, the preferred photolysis time ranges from 
approximately 30 to 120 seconds, most preferably, pho 
tolysis is effected in approximately 30 to 60 seconds. 
The distance of the light source from the sample is a 
determinative factor in the conditions of photolysis. A 
preferred method of the present invention uses an ultra 
violet light source having suf?cient intensity, about 
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6200 ].LW/Cm2, positioned at a set distance, about 1 cm 
from the sample, for a time suf?cient to effect photoac 
tivation, generally approximately 45 seconds. 
The labeled macromolecule is typically separated 
from the solution containing excess unbound sample 
and/or label by precipitation, although other recog 
nized methods of protein puri?cation are possible. Rec 
ognized methods of precipitation include, but are not 
limited to addition of an effective protein precipitating 
agent, such as trichloroacetic acid (TCA), perchloric 
acid (PCA), acetone, ammonium sulfate polyethylene 
glycol (PEG) or the like to the sample. PCA or ammo 
nium sulfate are the preferred precipitating agents in the 
present method, and PCA is the particularly preferred 
precipitating agent. 
The amount of precipitating agent is determined by 
the concentration of protein in the sample. The pre 
ferred concentration of the precipitating agent is that 
concentration which effectively precipitates the spe 
ci?c protein from solution. The most preferred concen 
tration of the precipitating agent is that amount which 
effectively precipitates the previously activated, 
photolabeled cerebral spinal ?uid sample. 
The precipitating agent can be mixed with the sample 
as a dry batch addition or in a calculated equivalent 
liquid form. The required mixing time may vary with 
the nature of the agent selected and the size or concen 
tration of the sample. However, the time required is that 
point after which essentially no additional protein is 
precipitated from the sample solution at the tempera 
ture selected. 
The precipitated protein may be separated from solu 
tion by any effective means, such as centrifugation, 
sedimentation or ?ltration. A preferred method of sepa 
ration of the precipitated protein from the solution is by 
centrifugation at a suf?cient speed and for a sufficient 
time to effectively isolate the protein into a pellet, for 
example by centrifugation at 13,000XG for 30 minutes. 
However, the parameters vary with the nature of the 
solution. ’ ' 
To determine the effectiveness of the precipitation 
and separation procedures, both the pellet and the su 
pernatant ?uid are analyzed for protein content. 
The precipitated protein may be solubilized and any 
remaining reaction quenched by any effective, known 
method. The determination of the solubilizing agent 
would depend on the ultimate method of identifying the 
speci?c nucleotide binding protein. Therefore, such 
agents could include, e.g., sodium dodecyl sulfate 
(SDS) or urea, and certain stabilizing agents. 
Any azide remaining after photolysis may be de 
stroyed by the addition of dithiothreitol or its equiva 
lent, and potential phosphotransfer from the triphos 
phate derivative N3ATP or N3GTP may be inhibited 
by chelators such as EDTA. The preferred protein 
solubilizing agent is a detergent, particularly SDS, most 
preferably in a protein solubilizing mix (PSM), such as 
described by Potter & Haley in Meth. in Enzymol, 
9lz6l3~633 (1983) or by procedures standard to most 
published procedures. A particularly preferred concen 
tration of SDS in the mix is 10%, resulting in a concen 
tration of SDS to the ?nal sample of 4%. 
Solubilization can occur either at 0° C. or at higher 
temperatures without affecting the results. However, 
solubilization in the present invention is effective at 
room temperature. 
Upon solubilization, the protein sample is applied to a 
suitable support for separation of the protein fractions. 
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Support materials could include, e.g., polyacrylamide 
gels, ?lter paper, starch gels or blocks, cellulose or 
polyurethane foam. Any effective, known method of 
protein separation may be used, but preferably separa 
tion is by electrophoresis over denaturing or non 
denaturing gels, or over a gradient of either type. In the 
present method, protein separation is usually by electro 
phoresis on a denaturing gel. 
The nature of the sample and the size of the speci?c 
nucleotide binding protein determine the concentration 
of the gel used, which in turn determines the time for 
separation and the electrical current which must be 
applied to best achieve protein separation. The protein 
fractions of the present invention most preferably may 
be separated by electrophoresis on an SDS-polyacryla 
mide gel (SDS-PAGE) or by isoelectric focusing (IEF) 
or on two dimensional systems (IEFXSDS-PAGE). 
Typically, the sample is fractionated on a 10% poly 
acrylamide gel, run over a period of 2% to 3 hours, with 
constant amperage of 35 mA and an initial voltage of 
about 140 volts. Any standard electrophoresis equip 
ment can be utilized. 
The resultant gels are exposed to X-ray film and 
visualized by autoradiography according to methods 
well known in the art. The gels can also be stained to 
determine the presence of the unique speci?c protein 
band or to ascertain that differences in the amount of 
photolabel incorporation are not due to drastic changes 
in the protein levels. Many known protein staining 
methods are widely recognized, e.g., Coomassie Bril 
liant Blue R (CBB) or silver staining. CBB is a com 
monly used stain that detects proteins based on a hydro 
phobic interaction between the proteins and the dye. 
Although any available staining method can be used 
which effectively distinguishes the speci?c nucleotide 
binding protein, CBB is the fastest and most economical 
for the present method. 
Most preferably, each completed SDS~PAGE gel is 
stained with an effective amount of CBB to stain the 
selected protein fragments. However, many times pro 
teins can be detected by photolabelling that cannot be 
detected by any protein staining procedure. In particu 
lar, the completed gel is immersed in a 10% CBB (W/v) 
solution for about 1 hour. Then the gel is destained in a 
solution to effectively remove excess stain. Particularly 
preferred is a destaining solution of 5% acetic acid and 
10% isopropyl alcohol applied for 10418 hours. 
Finally, the speci?c binding protein fragments may 
be visualized by standard autoradiography techniques. 
The use of an intensifying screen effectively accelerates 
the visualization process of autoradiography. By the 
method of the present invention, the stained gel is dried, 
and then exposed to DuPont Cronex 4 X-ray ?lm. The 
autoradiographic procedure is for variable time periods 
depending on the speci?c activity of the probe photoin 
serted into the proteins of each experimental sample. 
Alternately, if maintained at —70° C., the gel can be 
subjected to autoradiographic procedures while still in 
the gel state. 
The amount of protein, as well as the radioactivity 
incorporated into each protein, can be quanti?ed by 
known methods including, but not limited to, densito 
metric scans of the exposed X-ray ?lm, or of the stained 
gel, or by liquid scintillation spectrometry of the protein 
band following excision from the gel. 
Analyses of cerebral spinal fluid taken from human 
patients suffering from certain neurological or psychiat 
ric diseases or disorders, when labeled with the appro 
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priate, subsequently activated, radioactive photoaf?nity 
probe, reveals a disease-speci?c biochemical marker by 
which an existing disease state can be characterized. 
For example, a protein band having an apparent molec 
ular weight of about 68,000 Dil0% is found in the 
cerebral spinal ?uid of normal human subjects, visual 
ized by a subsequently activated, radioactive photoaf 
fmity probe, e.g., [32P]8N3cAMP. More particularly, 
the identi?ed protein band has an approximate molecu 
lar weight of 68 kD. Moreover, a fragment of the same 
size is recognized in cerebral spinal ?uid samples taken 
from patients afflicted with neurological diseases other 
than Alzheimer’s disease. 
By comparison, the cerebral spinal ?uid of human 
patients suffering from Alzheimer’s disease, is charac 
terized by an absence of photodetection of the protein 
fragment having an approximate weight of 68 kD, as 
visualized by photolabeling by, for example, 
[32P]8N3cAMP (see FIG. 2). 
Furthermore, the cerebral spinal ?uid of human pa 
tients suffering from various neurological and psychiat 
ric disorders, labeled with a subsequently activated, 
radioactive photoaf?nity probe, is found to have unique 
speci?c nucleotide binding proteins which can provide 
a distinctive means of diagnosing particular diseases. 
For example, a characteristic protein band having an 
apparent molecular weight of about 42,000 Dil0% is 
found in the radioactive photoaf?nity labeled cerebral 
spinal ?uid of Alzheimer’s disease patients using 
[32P]8N3ATP. More particularly, the Alzheimer’s dis 
ease-speci?c identi?ed protein band has an approximate 
molecular weight of 42 kD. 
By comparison, a systematic survey of the cerebral 
spinal ?uid taken from normal human subjects and la 
beled with a similar subsequently activated, radioactive 
photoaf?nity probe (i.e., [32P]8N3ATP), shows no pro 
tein fragment having an approximate weight of 42 kD 
being photolabeled. Thus, the identi?ed protein is 
unique to Alzheimer’s disease patients. There is appar 
ently no identi?ed corresponding protein fragment con 
tained in the cerebral spinal ?uid of normal human 
subjects. 
In addition to being photolabeled with the radioac 
tive photoprobe, the 42,000 M, protein may be shown to 
interact with ATP, a naturally occurring nucleotide 
that is the phosphate donor for many protein kinases 
and synthetases (last four lanes_FIG. 1). Therefore, 
based on the selectivity, the Alzheimer’s disease 
speci?c protein may be identi?ed as an ATP binding 
protein of about 42,000 M,. Furthermore, the same 42 
kD protein can be photolabeled with 8-azido-GTP, 
de?ning the speci?c protein as an ATP and GTP bind 
ing protein. However, the 42,000 M, protein binds ATP 
with higher affinity. 
Therefore, the human cerebral spinal ?uid samples 
can be reliably and accurately distinguished into two 
groups. The cerebral spinal ?uid samples taken from 
Alzheimer’s disease patients show photoinsertion of 
[32P]8N3ATP or [32P]2N3ATP into the identified dis 
ease-speci?c 42 kD protein, but an absence of photoin 
sertion of [32P]8N3cAMP in the normal 68 kD protein. 
Whereas, the samples taken from control subjects, unaf 
?icted by Alzheimer’s disease, show photoinsertion of 
[32P]8N3cAMP into a normal 68 kD protein, but no 
photoinsertion of either [32P]8N3ATP or [32P]2N3ATP 
into a 42 kD protein. The comparative analyses of cere 
bral spinal ?uid samples from Alzheimer’s disease pa 
tients and from normal human subjects, photolabeled 
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with a GTP analog, con?rm the results observed when 
the 42 kD protein is photo-labeled with the photoaf 
fmity probe of ATP. 
Based on mixing experiments of cerebral spinal ?uid 
taken from control subjects (in which the 68 kD protein 
is photolabeled) and samples of Alzheimer’s disease 
patients’ cerebral spinal ?uid (in which the 68 kD pro 
tein does not photolabel), it may be shown by the pres 
ent invention that a component of the Alzheimer’s dis 
ease cerebral spinal ?uid apparently prevents photola 
beling of the 68 kD protein of normal, control sample 
cerebral spinal ?uid with [32P]8N3cAMP. 
By the present invention, the Alzheimer’s disease 
specific 42,000 M, protein could be further identi?ed as 
glutamine synthetase. Mammalian glutamine synthetase 
is an enzyme with 42,000 M, subunits that catalyzes the 
following reaction: 
glutamate+NH4+ATP—>glutamine+ADP+ P, 
Further, it has been suggested that metabolism of gluta 
mate is altered in Alzheimer’s disease (AD) since those 
sections of the diseased brain which have become dys 
functional show very low levels of glutamate. More 
over, the neuronal cells that die in Alzheimer’s disease 
patients are glutamate sensitive cells. 
Glutamine synthetase can also be detected by measur 
ing the enzymatic catalytic conversion of substrates to 
products. Recognized detection techniques include, for 
example, measuring the catalytic conversion of 
[14C] glutamate to [14C]glutamine or [a32P]ATP to [a32 
P]ADP. Such methods of measuring catalytic conver 
sion are applicable to the detection of the Alzheimer’s 
disease-speci?c 42,000 M, protein of the present inven 
tion. 
The 42,000 M,protein is present in the cerebral spinal 
?uid of Alzheimer’s disease patients in very small quan 
tities. However, other than albumin and a protein of 
about 28,000 M,, the 42,000 M, protein is the major 
protein known to photolabel with either 8N3ATP or 
2N3ATP at the concentrations used. Therefore, by 
using the technique of photoaf?nity labeling and the 
materials and methods of the present invention, it is 
possible to detect a very minor protein of cerebral spi~ 
nal ?uid that interacts with ATP and GTP, and which 
appears to be unique in the cerebral spinal ?uid of clini 
cally diagnosed Alzheimer’s disease patients. 
Also important for the diagnosis of other disease 
states is the dramatic appearance of other smaller mo 
lecular weight proteins that photolabel only after ?ltra 
tion. One of these small proteins is tumor necrosis factor 
(T NF) which is proposed to be elevated in several dis 
ease states, including ischemia and AD. Also present is 
acidic ?broblast growth factor (aFGF). Studies with 
several different CSFs from neurological diseases show 
that these proteins change dramatically in different 
disease states. 
Other biological response modi?ers (i.e., cytokines, 
growth factors, etc.) reportedly in this lower molecular 
weight region of CSF ?uids include nerve growth fac~ 
tor (NGF), interleukin-1 (IL-1), interleukin-2 (IL-2), 
and basic ?broblast growth factor (bFGF). Fluid levels 
of each of these factors have been postulated to be in 
volved in various disease states. Each of these biological 
response modi?ers, in puri?ed form, are photolabeled 
with nucleotide photoaf?nity probes (Campbell et al, 
Proc. Natl. Acad. Sci. 87:1243-1246 (1990); Mann et at, 
Peptide Research 4:79-83 (1991); Shoemaker et al, Pro 






